Linical Co., Ltd.
2183.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.52B
Close$
$575.50
187.8% upside
Current Fair Value
187.8% upsideUndervalued by 187.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.52 Billion |
|---|---|
| Enterprise Value | $1.88 Billion |
| Dividend Yield | $8.00 (4.00%) |
| Earnings per Share | $-147.41 |
| Beta | 0.38 |
| Outstanding Shares | 22,586,431 |
Return
| Return on Equity | -117.97% |
|---|---|
| Return on Assets | -34.25% |
| Return on Invested Capital | -56.54% |
Valuation & Multiples
| P/E Ratio | -1.19 |
|---|---|
| PEG | -0.46 |
| Price to Sales | 0.57 |
| Price to Book Ratio | 1.41 |
| Enterprise Value to Revenue | 0.24 |
| Enterprise Value to EBIT | -0.7 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.08 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Linical Co., Ltd.
577 employees
CEO: Kazuhiro Hatano Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of pro...